ALMS Alumis Inc.

$ALMS they need to file that fda application asap and seek a partner for commercialization. They’ve got a good product going via their psoriasis drug.. let’s hope management doesn’t botch this opportunity.

$ALMS has new Phase 3 data showing rapid, durable scalp clearance and itch relief for psoriasis, keeping NDA filing on track for Q4 2026.

$ALMS the short thesis on this is now dead after the bullish confirmation from the company on phase 3 results. Tax loss sellers from the largest volume first week after the big drop are now eligible to buy back after the wash sale window, with more and more eligible every day. The 6.6x bottoming range held and bounced, the big boys have a green light to accumulate now.

$ALMS I thought about it - the only possible reason that the stock is dropping like this, could be that they actually over spent their cash, and they need to seek funding soon. with their cash level, they could not afford to fund the commercial of psoriasis drug alone. and they could not fund the phase 3 lupus subpopulation patients. so the potential buyers or partners are squeezing them with tough negotiations. next earnings we may see how much cash they actually have left.

$ALMS my average price is 7.79 dollars, I am fully all in, probably I am taking a huge risk but I believe I can easy double my money

$ALMS cannot believe Otezla generates roughly $2.1 billion to $2.3 billion in annual revenue for Amgen. According to Amgen’s official financial reports, its recent full-year global sales figures are: • 2025: $2.27 billion (a 7% increase year-over-year) • 2024: $2.10 billion. why ALMS is not worth anything? weird

$ALMS why the short interest is so low after down so much? As of Sep 15, the short interest is only like 6% to 7%. I was assuming a large short ratio.

$ALMS Relax ,you shorts will come back from the t1👀 $100$ open . It would be tough to wake up to ⏰️ though ...GL 😕 😒

$ALMS Initial entry at $3, followed by a second at $2, but proceed with caution, as the FDA could reject Alumis's therapy, which would cause the company to fail.

$ALMS boy that is one ugly chart. I don't quite understand why the stock is behaving this way, the bad news was way overdone. I have seen stocks like this stay at the lows, even make new lows, for a very long time and never recover. This seems to be the case here.